40614-20-8

Basic information

• Product Name: 3-(2'-Hydroxyphenyl)-3,3-dimethylpropanol
• Synonyms: 3-(2'-Hydroxyphenyl)-3,3-dimethylpropanol
• CAS NO: 40614-20-8
• Molecular Weight: 180.247
• Mol File: 40614-20-8.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: 3-(2'-Hydroxyphenyl)-3,3-dimethylpropanol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2'-Hydroxyphenyl)-3,3-dimethylpropanol(40614-20-8)
• EPA Substance Registry System: 3-(2'-Hydroxyphenyl)-3,3-dimethylpropanol(40614-20-8)

Safety Data

• Hazardous Substances Data: 40614-20-8(Hazardous Substances Data)

Upstream product

• 924-50-5 Methyl 3,3-dimethylacrylate 
• 638-10-8 ethyl 3-methylbut-2-enoate 
• 108-95-2 phenol 
• 29598-22-9 4,4-dimethyl-2-oxo-chroman 
• 54897-52-8 phenyl 3,3-dimethylacrylate 
• 3350-78-5 3,3-Dimethylacryloyl chloride 

Downstream Products

• 40614-27-5 4,4-dimethylchromane 
• 81246-49-3 3-<2-((methylthio)methoxy)phenyl>-3,3-dimethyl-1-propanol 

Relevant articles and documents

CHROMAN-SUBSTITUTED, TETRAHYDROQUINOLINE-SUBSTITUTED AND THIOCHROMAN-SUBSTITUTED HETEROAROTINOIDS AS ANTI-CANCER AGENTS

Chemical compounds that inhibit cancer cell growth are provided. The compounds are heteroarotinoids and derivatives thereof with oxygen, nitrogen or sulfur in chroman systems, tetrahydroquinoline systems, and tetrahydrothiochroman systems.

Design, Synthesis, and Cellular Uptake of Oligonucleotides Bearing Glutathione-Labile Protecting Groups

Glutathione-labile protecting groups for phosphodiester moieties in oligonucleotides were designed, synthesized, and incorporated into oligonucleotides. The protecting groups on the phosphodiester moieties were cleaved in a buffer containing 10 mM glutath

HYDROGEN SULFIDE PRECURSORS AND CONJUGATES THEREOF

The present invention provides methods of forming hydrogen sulfide. The methods include contacting a precursor compound with an unmasking agent; wherein the precursor compound comprises a hydrogen sulfide releasing moiety and a masked nucleophile; and wherein the contacting is conducted under conditions sufficient for cyclization of the precursor compound via lactone or lactam formation; thereby releasing hydrogen sulfide from the precursor compound. Hydrogen sulfide precursor compounds according to Formula (I) are also described, as well as methods for treating diseases and conditions using hydrogen sulfide precursors.